PMID- 26591107
OWN - NLM
STAT- MEDLINE
DCOM- 20160114
LR  - 20151120
IS  - 1427-440X (Print)
IS  - 1427-440X (Linking)
VI  - 60
IP  - 2
DP  - 2014
TI  - [PROGRESS IN THE PATHOGENESIS, DIAGNOSIS AND TREATMENT OF SYSTEMIC 
      ANCA-ASSOCIATED VASCULITIS].
PG  - 44-9
AB  - Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a group of 
      systemic diseases characterized by necrotizing inflammation of small and medium 
      size vessels, without immunologic deposits, and with the presence of specific 
      serum antibodies. Recent genetic and cohort studies should improve the 
      comprehension of the pathogenesis of AAV, the stratification of patients into 
      homogenous groups, and lead to therapeutic implications. Immunosuppressive 
      therapy of AAV includes two major periods: induction of remission and maintenance 
      therapy. Therapy should be chosen individually, not only depending on the stage 
      and severity of the disease, but also on genetic and some prognostic factors. 
      Previous randomized trials and clinical observations show some possible 
      limitations of treatment with cyclophosphamide and steroids. Rytuximab seems to 
      be a good alternative in those patients in induction therapy as well as in 
      maintenance therapy.
FAU - Zdrojewski, Zbigniew
AU  - Zdrojewski Z
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - POSTEPY W PATOGENEZIE, DIAGNOSTYCE I LECZENIU UKLADOWYCH ZAPALEN NACZYN 
      ZWIAZANYCH Z PRZECIWCIALAMI PRZECIWGRANULOCYTARNYMI.
PL  - Poland
TA  - Ann Acad Med Stetin
JT  - Annales Academiae Medicae Stetinensis
JID - 7506854
RN  - 0 (Immunologic Factors)
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*diagnosis/*etiology
MH  - Cyclophosphamide/therapeutic use
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Immunosuppressive Agents/therapeutic use
MH  - Remission Induction
MH  - Rituximab/therapeutic use
EDAT- 2014/01/01 00:00
MHDA- 2016/01/15 06:00
CRDT- 2015/11/24 06:00
PHST- 2015/11/24 06:00 [entrez]
PHST- 2014/01/01 00:00 [pubmed]
PHST- 2016/01/15 06:00 [medline]
PST - ppublish
SO  - Ann Acad Med Stetin. 2014;60(2):44-9.